Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Gamma secretase inhibitors
20 evidence topics · 10 sources
Nirogacestat: FDA-approved indication and mechanism
Nirogacestat: recommended dosage and dose modifications
Nirogacestat warnings: diarrhea
Nirogacestat warnings: ovarian toxicity
Nirogacestat warnings: hepatotoxicity
Nirogacestat warnings: non-melanoma skin cancers
Nirogacestat warnings: electrolyte abnormalities
Nirogacestat warnings: hypersensitivity reactions, added August 2026
Nirogacestat warnings: embryo-fetal toxicity
Nirogacestat: drug interactions
DeFi phase 3 trial: design
“We conducted a phase 3, international, double-blind, randomized, placebo-controlled trial of nirogacestat in adults with progressing desmoid tumors according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Patients were assigned in a 1:1 ratio to receive the oral γ-secretase inhibitor nirogacestat (150 mg) or placebo twice daily. The primary end point was progression-free survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From May 2019 through August 2020, a total of 70 patients were assigned to receive nirogacestat and 72 to receive placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
DeFi phase 3 trial: efficacy
“The risk of disease progression or death was 71% lower in the nirogacestat group than in the placebo group (hazard ratio, 0.29; 95% confidence interval [CI], 0.15 to 0.55; P<0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The likelihood of being event-free at 1 year was 85% (95% CI, 73 to 92) with nirogacestat and 53% (95% CI, 40 to 64) with placebo. The likelihood of being event-free at 2 years was 76% (95% CI, 61 to 87) with nirogacestat and 44% (95% CI, 32 to 56) with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The percentage of patients with a confirmed objective response was 41% in the nirogacestat group and 8% in the placebo group (P<0.001). Complete responses were observed in 7% of the patients in the nirogacestat group and no patients in the placebo group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Significant between-group differences in secondary patient-reported outcomes, including pain, symptom burden, physical or role functioning, and health-related quality of life, were observed (P≤0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
DeFi phase 3 trial: safety
“Dose reductions due to adverse events were more frequently reported among patients receiving nirogacestat (42%) than among those receiving placebo (0%) and were attributed primarily to diarrhea, stomatitis, maculopapular rash, hypophosphatemia, hidradenitis, ovarian failure, and folliculitis. Adverse events led to discontinuation of the trial regimen in 14 patients (20%) in the nirogacestat group and 1 patient (1%) in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ovarian dysfunction (defined by the MedDRA preferred terms of amenorrhea, premature menopause, menopause, and ovarian failure) occurred in 27 of 36 women of childbearing potential (75%) receiving nirogacestat and in 0 of 37 receiving placebo. The median time to first onset of ovarian dysfunction was 8.9 weeks, and the median duration across ovarian dysfunction events was 19.1 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although long-term treatment with nirogacestat was shown to be feasible (median treatment duration, 20.6 months), the appropriate treatment duration is unknown.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
DeFi long-term follow-up through December 2024
“Here, long-term nirogacestat efficacy and safety were evaluated in patients randomly assigned to nirogacestat and followed through the final data cutoff date of December 19, 2024.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median (range) duration of exposure was 33.6 (0.3-61.8) months. Median PFS was not reached. The ORR with up to 4 years of nirogacestat treatment was 45.7% (32 of 70), with three additional partial and three additional complete responses since the primary analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 70 patients randomly assigned to nirogacestat in the DB phase, 39 continued in the OLE” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 33 and 15 patients received nirogacestat for at least 3 and 4 years, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No additional events (progression or death) occurred with additional exposure after year 2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was 34.3%, 41.4%, 44.3%, and 45.7% in patients who received nirogacestat for up to 1, 2, 3, and 4 years, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since the primary analysis, four patients discontinued nirogacestat because of TEAEs between years 2 and 4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Optimal duration of treatment and the presence and frequency of additional tumor responses after treatment discontinuation are not well defined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
DeFi ovarian toxicity: onset and resolution in females of reproductive potential
“This analysis further describes the incidence, presentation, and resolution of OT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“OT was identified in 75% (27 of 36) receiving nirogacestat and 0% (0 of 37) receiving placebo. As of October 24, 2022, investigators reported OT resolution in 78% (21 of 27) of patients, with median OT duration of 19.1 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Off-treatment resolution was reported in all 11 patients (100%) who stopped nirogacestat treatment” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Resolution was reported in 10 of 14 (71%) while on nirogacestat” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most FORP treated with nirogacestat experienced OT, with the majority resolving, including all who stopped treatment, suggesting that OT is transient.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Duration of nirogacestat treatment: DeFi investigators' reply on long-term use
“We do not endorse long-term uninterrupted treatment with nirogacestat as the standard of care. Still, as both groups of authors have acknowledged, the optimal treatment duration remains undefined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, patients in DeFi were censored at the time nirogacestat was discontinued and were followed for no more than 30 days after treatment discontinuation. Therefore, the absence of progression events after year 2 reflects only the cohort of patients who continued treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world nirogacestat use in the French compassionate use program (DeNi study)
“The DeNi study reports outcomes of patients treated with nirogacestat through the French compassionate use program. DeNi is a retrospective, real-world study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between February and June 2024, 55 patients with desmoid tumors were included (37 women).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Partial response and stable disease were observed in 33 (60%) and 17 patients (31%), respectively. The 1-year PFS rate was 76.2%, and 77.0% of patients remained without treatment change at 1 year, including patients with dose reductions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 49 patients with baseline pain, 38 (78%) experienced pain improvement under nirogacestat; 35 (71%) reduced or discontinued analgesics.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent side effects (all grades) were diarrhea (53%), fatigue (47%), and rash (29%). Thirteen patients (24%) required dose reduction: 11 for digestive adverse events (85%), 1 for mucositis, and 1 for fatigue with hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
NCCN guideline status as restated in a payer policy and in a DeFi publication
“Nirogacestat, an oral, targeted gamma secretase inhibitor, is the only US Food and Drug Administration–and European Commission–approved therapy for adults with progressing DT who require systemic treatment and is recommended as a preferred therapy by the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
European marketing authorisation of nirogacestat
“Approval from the European Commission was obtained in August 2025 and from the UK Medicines and Healthcare Products Regulatory Agency in January 2026.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, as of this writing, nirogacestat is still not widely available outside of the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote